INS and fatty liver disease: Nagata et al. (126), revealed the anti-obesity effect of glucoraphanin, precursor of sulforaphane, in HFD-fed mice, and found that 0.3% w/w glucoraphanin for oral administration for 14 weeks significantly reduced body weight, alleviated hepatic steatosis and improved insulin sensitivity in wild type mice but not in Nrf2 KO mice.